

William Douglas Cress

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6759228/publications.pdf>

Version: 2024-02-01

13
papers

226
citations

1307594

7
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

495
citing authors

#	ARTICLE	IF	CITATIONS
1	Trim28 Contributes to EMT via Regulation of E-Cadherin and N-Cadherin in Lung Cancer Cell Lines. PLoS ONE, 2014, 9, e101040.	2.5	54
2	E2F Inhibition Synergizes with Paclitaxel in Lung Cancer Cell Lines. PLoS ONE, 2014, 9, e96357.	2.5	39
3	E2F4 deficiency promotes drug-induced apoptosis. Cancer Biology and Therapy, 2004, 3, 1262-1269.	3.4	31
4	A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 838-849.	1.1	24
5	Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. Journal of Thoracic Oncology, 2017, 12, 1851-1856.	1.1	20
6	CDKN1C Negatively Regulates RNA Polymerase II C-terminal Domain Phosphorylation in an E2F1-dependent Manner. Journal of Biological Chemistry, 2010, 285, 9813-9822.	3.4	18
7	Necdin, a Negative Growth Regulator, Is a Novel STAT3 Target Gene Down-Regulated in Human Cancer. PLoS ONE, 2011, 6, e24923.	2.5	16
8	RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biology and Therapy, 2010, 10, 1123-1125.	3.4	6
9	Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. FEBS Open Bio, 2019, 9, 1689-1704.	2.3	6
10	E2F1. Cell Cycle, 2011, 10, 1718-1718.	2.6	5
11	CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. PLoS ONE, 2021, 16, e0252927.	2.5	3
12	A stitch in time and CDK9. Cell Cycle, 2017, 16, 823-824.	2.6	2
13	Loss of cellular identity in common pre-clinical models of serine/threonine kinase 11 (Liver kinase B1) loss. Cancer Treatment and Research Communications, 2021, 26, 100286.	1.7	2